VolitionRX (VNRX) Corporate presentation summary

Recent achievements

• Cat paper submitted; $5M milestone expected if published; Fujifilm Vet Systems launch on i10 platform.

• Expansion into non-sepsis disease areas and Mayo Clinic publication in trauma.

• Demonstrated utility of rapid, point-of-care finger-prick test in sepsis patients; DETECSEPS on track for first patient Q3.

• Reimbursement submission in preparation for Nu.Q Cancer; certification completed at three French hospitals.

• Peer-reviewed paper published for Nu.Q Discover; co-marketing agreement in place with Hologic.

Business model and commercialization

• Low-capex, low-opex model focused on commercial partnerships and out-licensing.

• Monetizes IP through upfront, milestone, and recurring revenue from licensing agreements.

• Broad geographic reach and large installed base through partners.

• Asset-light approach with no need for proprietary machines, labs, or sales reps.

• Multiple licensing deals targeted in human diagnostics for 2026.

Product portfolio and technology

• Multiple products launched, including Nu.Q Vet, Nu.Q Nets, Nu.Q Cancer, Capture Seq, and Nu.Q Discover.

• Platform-agnostic, low-cost routine tests adaptable to various diagnostic workflows.

• 74 patents granted with coverage up to 2044; strong IP position.

• Capture Seq enables world-first isolation of 99% pure tumor-associated DNA from liquid biopsy.

• Rapid, point-of-care finger-prick test for sepsis expands access to underserved regions.